Navigation Links
Neutrogena(R) Dermatologics Introduces skin iD(TM), the First Personalized Acne Solution

Clinically proven to be 2X more effective in acne clearing, and 2X more

effective in acne prevention vs. the leading acne system

LOS ANGELES, June 12 /PRNewswire/ -- Neutrogena(R) Dermatologics, a unit of the #1 dermatologist recommended skincare brand Neutrogena(R), introduces skin iD(TM), the first personalized acne solution clinically proven to treat and prevent acne. skin iD is a precise, targeted and individualized approach to treating and preventing acne.

(Photo: )

In a clinical trial testing 500 people with different skin, acne and lifestyles, 100% of people using skin iD got clearer, healthier-looking skin. skin iD is currently the only non-prescription acne solution on the market that has conducted a double blind, randomized, placebo-controlled clinical trial -- the "gold standard" in testing methodology. This clinical trial demonstrated skin iD's power to work significantly better than the top selling acne regimen in treating 16 different signs of acne.

skin iD was developed by Neutrogena(R) Dermatologics with a group of leading dermatologists, scientists and market researchers, charged to create a customized skin-clearing solution specifically designed to treat acne on a case-by-case basis without a prescription. skin iD is comprised of a skin evaluation, an exclusive product line and a comprehensive Web site to treat each individual's acne needs.

Exclusively available on, and showcased through a series of infomercials, skin iD is the first proposition of its kind on the market. "We wanted to create a highly effective acne solution to meet the needs of individuals who are not satisfied with their existing acne regimen," states Jim Colleran, President, Neutrogena Corporation. "skin iD was developed with an innovative one-on-one approach. We determined that offering consumers access to skin iD through a dedicated Web site or by phone would allow for the dialogue necessary to evaluate their unique skincare needs and provide a personalized regimen."

skin iD utilizes a breakthrough skin and lifestyle evaluation tool, which contains a patent-pending algorithm that provides a personalized skincare regimen based on the specific skincare needs of each individual consumer. skin iD is formulated with two leading acne-fighting medicines, Salicylic Acid and Benzoyl Peroxide, included in more than 25 customized acne skincare regimens that cleanse, treat and protect for significantly improved skin.

To launch skin iD, Neutrogena(R) Dermatologics has enlisted singer/actress Katharine McPhee. Best known for her success on "American Idol" and her first single "Somewhere Over the Rainbow," McPhee is truly a role model for young girls, who understands the emotional impact associated with acne and the importance of finding a solution. Katharine will appear in infomercials and be featured on beginning in May 2008. McPhee will make her big screen debut in August, starring in "The House Bunny" opposite Anna Farris, Emma Stone and Kat Dennings for Sony Pictures.

About Neutrogena(R):

A worldwide leader in premium, dermatologist-recommended skin, hair and cosmetics products, Neutrogena(R) Corporation has been providing consumers with health and beauty improvements for over 40 years. The Company manufactures and markets a line of premium priced skin and hair care products that are distributed in more than 70 countries. Headquartered in Los Angeles, Neutrogena(R) is a subsidiary of Johnson & Johnson, world's most comprehensive and broadly based health care products company.

SOURCE Neutrogena
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Update: Oscar-Nominated Actress Signs on as Neutrogena(R) Brand Ambassador
2. Oscar-Nominated Actress Signs on as Neutrogena(R) Brand Ambassador
3. Wolters Kluwer Health Introduces Formulary Facts(TM), a Formulary Analytics Tool that Sets the Standard for Accuracy and Ease-of-Use
4. IMTEC Introduces the SPRITE CT System
5. COSE Introduces Health Incentives, Wellness Programs for Medium-Size Businesses
6. Zebra Technologies Introduces HC100(TM) Patient I.D. Wristbanding Solution
7. PharMEDium Introduces Innovative New Admixture Label Design
8. Alaven Pharmaceutical Introduces Kit for UC Patients
9. Omron Healthcare Introduces New Device Drivers Built on Microsoft HealthVault
10. Answers From Nature Introduces 100% Non-China Ingredients for Dietary Supplements
11. Braemar Introduces the DL900 Advanced Holter Monitor
Post Your Comments:
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... , ... In an ongoing Clinical Study conducted by an independent physician, Andrew ... is evaluating the efficacy of its product and its disinfection protocol. This study is ... May 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary ... Periwinkle Pioneers, nominated by the public, will receive special recognition throughout 2016 as ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 --> ... devices was valued at $11,171.1 million in 2014, and ... 5.7% during 2015 - 2022. The global market is ... of diabetes. In addition, the increase in obese population ... to the growth of the market. Furthermore, technological advancements ...
Breaking Medicine Technology: